 |
ViroPharma to Participate in Two May Healthcare Investor Conferences
May 2, 2012
|
14.1 KB |
|
| |
EXTON, Pa., May 2, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the Deutsche Bank 37th Annual Healthcare Conference at 2:50 P.M. ET on Monday, May 7, 2012. The conference is being held at the InterContinental Hotel in Bost...
|
|
ViroPharma Incorporated Reports First Quarter 2012 Financial Results
May 1, 2012
|
32.3 KB |
|
| |
EXTON, Pa., May 1, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the first quarter ended March 31, 2012.
Since December 31, 2011, we:
Achieved $136 million in quarterly net product sales, including $68 million in worldwide net sales of Cinryze® (C1 esterase inhibitor [hum...
|
|
ViroPharma To Release 2012 First Quarter Financial Results On May 1, 2012
Apr 23, 2012
|
14.2 KB |
|
| |
EXTON, Pa., April 23, 2012 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) first quarter financial results for 2012 are expected to be released on Tuesday, May 1, 2012 before the open of the U.S. financial markets.
The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the c...
|
|
ViroPharma Provides Update on Status of Citizen Petition Regarding Bioequivalence and Exclusivity for Vancocin® (vancomycin hydrochloride, USP) Capsules
Apr 10, 2012
|
21.7 KB |
|
| |
EXTON, Pa., April 10, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the U.S. Food and Drug Administration (FDA) denied the citizen petition (Docket # FDA-2006-P-0007) filed by ViroPharma on March 17, 2006 related to the FDA's proposed in vitro method for determining bioequivalence of abbreviated new drug applications (...
|
|
ViroPharma Launches Hereditary Angioedema Facebook App to Encourage Education and Diagnosis of Hereditary Angioedema Through Discussion of Family History
Mar 29, 2012
|
19.9 KB |
|
| |
EXTON, Pa., March 29, 2012 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM), the maker of Cinryze® (C1 esterase inhibitor [human]), today launched the hereditary angioedema (HAE) Family Tree Facebook Application (app) to help raise awareness of HAE and to encourage testing and diagnosis of the rare, potentially life-threatening disease. ...
|
|
ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20)
Mar 6, 2012
|
24.9 KB |
|
| |
ORLANDO, Fla., March 6, 2012 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) and Halozyme Therapeutics (Nasdaq: HALO) today announced the presentation of positive data from ViroPharma's Phase 2 subcutaneous trial of Cinryze® (C1 esterase inhibitor [human]) in combination with Halozyme's Enhanze™ technology, a proprietary drug deli...
|
|
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
Feb 28, 2012
|
36.4 KB |
|
| |
EXTON, Pa., Feb. 28, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the fourth quarter and year ended December 31, 2011.
In 2011, we:
Achieved a record $544 million in annual net product sales, including $251 million in net sales of Cinryze® (C1 esterase inhibitor [human]), and $289 m...
|
|
Pivotal Data Demonstrating Efficacy of Plenadren® (Hydrocortisone, Modified Release Tablet) in Adrenal Insufficiency Published in the Journal of Clinical Endocrinology and Metabolism
Feb 16, 2012
|
20.8 KB |
|
| |
EXTON, Pa., Feb. 16, 2012 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced that data from the pivotal study for their orphan drug Plenadren® (hydrocortisone, modified release tablet) were published in the Journal of Clinical Endocrinology and Metabolism (JCEM), a leading scientific journal for endocrinology. Plenadren was...
|
|
ViroPharma to Release 2011 Fourth Quarter and Full Year Financial Results on February 28, 2012
Feb 15, 2012
|
14.3 KB |
|
| |
EXTON, Pa., Feb. 15, 2012 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) fourth quarter and year end financial results for 2011 are expected to be released on Tuesday, February 28, 2012 before the open of the U.S. financial markets.
The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same...
|
|
ViroPharma to Participate in Two Upcoming Healthcare Investor Conferences
Feb 14, 2012
|
14.0 KB |
|
| |
EXTON, Pa., Feb. 14, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the Leerink Swann 2012 Global Healthcare Conference at 3:00 P.M. ET on Thursday, February 16, 2012. The conference is being held at the Waldorf Astoria in N...
|
|
ViroPharma Provides Update on Industrial Scale Supplement for Cinryze® (C1 Esterase Inhibitor [Human])
Feb 7, 2012
|
19.7 KB |
|
| |
EXTON, Pa., Feb. 7, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the U.S Food and Drug Administration (FDA) issued a complete response letter regarding Cinryze® (C1 Esterase Inhibitor [Human]) industrial scale manufacturing expansion activities. Specifically, the FDA has three comments related to a portion of the...
|
|
Health Canada Grants Priority Review Status For New Drug Submission (NDS) For Cinryze™ (C1 Inhibitor [human])
Jan 13, 2012
|
20.5 KB |
|
| |
EXTON, Pa., Jan. 13, 2012 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced that Health Canada has granted the company Priority Review status for its New Drug Submission (NDS) for Cinryze™ (C1 inhibitor [human]). Priority Review allows for an expedited review of critical new drugs faster than a standard review. ViroPharm...
|
|
ViroPharma Provides 2012 Outlook
Jan 5, 2012
|
26.1 KB |
|
| |
EXTON, Pa., Jan. 5, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will provide an overview of the company's business during the 30th Annual J.P. Morgan Healthcare Conference. The presentation will be webcast live at 7:30 P.M. ET (4:30 P.M. PT) o...
|
|
ViroPharma Announces Appointment of Julie H. McHugh to Board of Directors
Jan 3, 2012
|
14.5 KB |
|
| |
EXTON, Pa., Jan. 3, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the appointment of Julie H. McHugh to its board of directors.
Ms. McHugh brings a wealth of pharmaceutical and health care industry experience and leadership to ViroPharma's Board of Directors. She is currently the chief operating officer of Endo...
|
|
ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma
Dec 22, 2011
|
21.9 KB |
|
| |
EXTON, Pa. and SAN DIEGO, Dec. 22, 2011 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced that it has entered into an exclusive option to acquire Meritage Pharma, Inc., a private company based in San Diego, CA focused on developing oral budesonide suspension (OBS) as a treatment for eosinophilic esophagitis (EoE), a chronic inf...
|
|
ViroPharma Announces Approval of Modernized Labeling for Vancocin® (vancomycin hydrochloride, USP) Capsules
Dec 14, 2011
|
23.3 KB |
|
| |
EXTON, Pa., Dec. 14, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the modernization of labeling for Vancocin® (vancomycin hydrochloride, USP) Capsules made effective through the U.S. Food and Drug Administration's (FDA) approval of a supplemental new drug application (sNDA). The company also provided updates on ...
|
|
ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
Dec 6, 2011
|
23.6 KB |
|
| |
EXTON, Pa., Dec. 6, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) and Halozyme Therapeutics (Nasdaq: HALO) today announced positive top line data from ViroPharma's open-label, multiple dose Phase 2 clinical trial designed to evaluate the safety, pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze® (C1 ...
|
|
ViroPharma to Participate in Two December Healthcare Investor Conferences
Dec 5, 2011
|
13.0 KB |
|
| |
EXTON, Pa., Dec. 5, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Robert Doody, assistant director of investor relations of ViroPharma, will present at the 2011 Deutsche Bank BioFEST Conference at 8:35 A.M. ET on Tuesday, December 6, 2011. The conference is being held at the Four Seasons Hotel in Boston.
C...
|
|
ViroPharma Completes Acquisition of DuoCort Pharma AB
Nov 15, 2011
|
20.7 KB |
|
| |
EXTON, Pa., Nov. 15, 2011 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced that it completed its acquisition of DuoCort Pharma AB, a private company based in Helsingborg, Sweden focused on improving glucocorticoid replacement therapy. The acquisition of Duocort Pharma AB further expands ViroPharma's orphan disease commercial ...
|
|
DuoCort Pharma's Orphan Drug Plenadren® Granted European Marketing Authorization for Adrenal Insufficiency
Nov 7, 2011
|
20.1 KB |
|
| |
HELSINGBORG, Sweden and EXTON, Pa., Nov. 7, 2011 /PRNewswire/ -- The Swedish specialty pharma company, DuoCort Pharma, announced today that the European Commission has granted a European Marketing Authorisation for Plenadren® (hydrocortisone, modified release tablet), an orphan drug for treatment of adrenal insufficiency in adults, bringing t...
|
|
|